# Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers

> **NCT01301742** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 10773
- **DRUG:** Gemfibrozil
- **DRUG:** BI 10773

## Key facts

- **NCT ID:** NCT01301742
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01301742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01301742, "Relative Bioavailability of Single Dose Empagliflozin (BI 10773) When Co-administered With Multiple Doses of 600 mg Gemfibrozil Compared to Single Dose Treatment With Empagliflozin (BI 10773) When Given Alone in Healthy Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01301742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*